FindTrial
Sign In

An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of standard of care +/- continuous R435(bevacizumab) treatment beyond progression of disease (PD) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after first (1st)-line treatment with bevacizumab plus a platinum doublet-containing chemotherapy

An open-label, randomized, Phase IIIb trial evaluating the efficacy and safety of standard of care +/- continuous R435(bevacizumab) treatment beyond progression of disease (PD) in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after first (1st)-line treatment with bevacizumab plus a platinum doublet-containing chemotherapy

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080221719
Enrollment
Unknown
Registered
2012-02-27
Start date
2012-02-27
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-squamous non-small cell lung cancer

Interventions

investigational material(s) Generic name etc : bevacizumab INN of investigational material : bevacizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigat

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Age >= 18 years. -Sex:Both -Ability to comply with the protocol. -Histologically or cytologically confirmed non-squamous NSCLC -At least 1 unidimensionally measurable lesion meeting RECIST (v.1.1) criteria. -Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2.

Exclusion criteria

Exclusion criteria: -Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component. -EGFR-mutation-positive disease according to local laboratory testing.

Design outcomes

Primary

MeasureTime frame
-To assess the efficacy of continuous R435 treatment beyond PD1 as measured by overall survival(OS). -To assess the safety of R435 treatment across multiple lines of treatment.—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026